
SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. (SWTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SWTX · as of Jun 30, 2025
Ownership Breakdown
249
Institutional Holders
▼ 103 vs Q1
$3.53B
Total Inst. Value
▲ $239.13M vs Q1
75.35M
Shares Outstanding
freeFloat 96.81%
75.14M
13F Shares Held
▲ 603,087 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SWTX largest shareholders · institutional ownership
Q2 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 7.26M | 9.70% | 9.70% | $341.18B | Aug 12, 2025 | ▲ 1.01M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 7.13M | 9.52% | 9.52% | $335.09B | Aug 11, 2025 | ▲ 48.4K |
GLAZER CAPITAL, LLC biological products, (no diagnostic substances) | 4.11M | 5.48% | 5.48% | $193.04B | Aug 14, 2025 | NEW |
HUDSON BAY CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 3.53M | 4.71% | 4.71% | $165.84B | Aug 18, 2025 | NEW |
FIL LTD biological products, (no diagnostic substances) | 3.01M | 4.02% | 4.02% | $141.63B | Aug 14, 2025 | NEW |
STATE STREET CORP biological products, (no diagnostic substances) | 2.99M | 4.00% | 4.00% | $140.69B | Aug 14, 2025 | ▲ 77.7K |
TIG ADVISORS, LLC biological products, (no diagnostic substances) | 2.61M | 3.49% | 3.49% | $122.69B | Aug 14, 2025 | ▲ 2.36M |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 2.28M | 3.04% | 3.04% | $106.92B | Aug 14, 2025 | ▲ 1.65M |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 2.17M | 2.90% | 2.90% | $102.15B | Aug 14, 2025 | ▲ 570.4K |
BERYL CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.12M | 2.83% | 2.83% | $99.50B | Aug 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2025 vs prior quarter
Q2 2025
29
Increased
+18.98M shares14
New Positions
first time holders7
Decreased
−3.40M shares0
Sold Out
fully exitedNet shares change (top 50)
+15.58M
+18.98M / −3.40M
Net new holders
+36
14 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SWTX insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
87
Sell transactions
0.00
Buy/Sell ratio
$7M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 33,778 | — | — | 0 | Form 4 ↗ |
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 3,868 | $1.65 | $6.4K | 0 | Form 4 ↗ |
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 149,470 | $2.30 | $343.8K | 0 | Form 4 ↗ |
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 100,000 | $33.66 | $3.37M | 0 | Form 4 ↗ |
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 240,000 | $27.64 | $6.63M | 0 | Form 4 ↗ |
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 169,712 | — | — | 0 | Form 4 ↗ |
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 120,000 | $38.40 | $4.61M | 0 | Form 4 ↗ |
Edris Badreddin Chief Operating Officer | Jul 1, 2025 | D-Return | 78,960 | $43.00 | $3.40M | 0 | Form 4 ↗ |
LYNCH DANIEL director | Jul 1, 2025 | D-Return | 29,983 | $18.00 | $539.7K | 0 | Form 4 ↗ |
LYNCH DANIEL director | Jul 1, 2025 | D-Return | 7,464 | $38.03 | $283.9K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
SpringWorks Therapeutics, Inc. (SWTX) is primarily owned by institutional investors, who hold approximately 99.7% of total shares outstanding. Company insiders own approximately 3.19%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of SpringWorks Therapeutics, Inc. is BLACKROCK, INC., holding approximately 7.26 million shares — equal to 9.70% of outstanding shares — as of June 30, 2025.
A total of 249 institutional investors currently hold SWTX stock, with a combined institutional value of approximately $3.53 billion as of the most recent 13F filing period.
Frequently asked questions
SWTX ownershipSpringWorks Therapeutics, Inc. (SWTX) is primarily owned by institutional investors, who hold approximately 99.7% of shares. The largest shareholder is BLACKROCK, INC. with a 9.70% stake. Company insiders hold 3.19%. Data sourced from SEC Form 13F as of June 30, 2025.